Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.
We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.
We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.
LATEST NEWS FEED
Sign Up for News Alerts
For the latest on Ionis news and developments
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 12, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created with the goal of providing people with spinal muscular atrophy (SMA)
- Pivotal Phase 3 REVEAL study enrollment on track to complete in 2026 - CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 9, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the
CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 8, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025 , in New York . The agenda will feature presentations from members of the Ionis leadership team as well as a key thought
Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).